Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

J. Ciccolini · SciRah

Researcher profile · Semantic Scholar

J. Ciccolini

Share profile

J. Ciccolini — researcher profile on SciRah

h-index: 42
Works: 283
Citations: 6,084

Most-cited papers

Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors
M. Centanni, D. J. Moes, I. Trocóniz, J. Ciccolini +1 more
2019Clinical Pharmacokinetics326 citations Open access
Semantic Scholar
Population modeling of tumor growth curves and the reduced Gompertz model improve prediction of the age of experimental tumors
C. Vaghi, A. Rodallec, R. Fanciullino, J. Ciccolini +5 more
2020PLoS Comput. Biol.161 citations Open access
Semantic Scholar
All You Need to Know About DPYD Genetic Testing for Patients Treated With Fluorouracil and Capecitabine: A Practitioner-Friendly Guide.
F. Innocenti, Sarah C Mills, H. Sanoff, J. Ciccolini +2 more
2020JCO Oncology Practice59 citations Open access
Semantic Scholar
Cancer Immunotherapy Dosing: A Pharmacokinetic/Pharmacodynamic Perspective
F. Le Louedec, F. Leenhardt, Clémence Marin, E. Chatelut +2 more
2020Vaccines43 citations Open access
Semantic Scholar
Pharmacokinetics variability: Why nanoparticles are not just magic-bullets in oncology.
A. Rodallec, S. Benzekry, B. Lacarelle, J. Ciccolini +1 more
2018Critical reviews in oncology/hematology43 citations
Semantic Scholar
Current diagnostic and clinical issues of screening for dihydropyrimidine dehydrogenase deficiency.
M. Etienne-Grimaldi, N. Pallet, V. Boige, J. Ciccolini +7 more
2022European Journal of Cancer42 citations Open access
Semantic Scholar
Unraveling the complexity of therapeutic drug monitoring for monoclonal antibody therapies to individualize dose in oncology
E. Chatelut, J. Hendrikx, Jennifer H. Martin, J. Ciccolini +1 more
2021Pharmacology Research & Perspectives36 citations Open access
Semantic Scholar
Potential Role of Exosomes in the Chemoresistance to Gemcitabine and Nab-Paclitaxel in Pancreatic Cancer
A. Comandatore, B. Immordino, R. Balsano, M. Capula +4 more
2022Diagnostics32 citations Open access
Semantic Scholar
COVID-19 vaccine race: watch your step for cancer patients
R. Fanciullino, J. Ciccolini, G. Milano
2020British Journal of Cancer32 citations Open access
Semantic Scholar
Towards rational cancer therapeutics: optimizing dosing, delivery, scheduling and combinations.
Florent Ferrer, R. Fanciullino, G. Milano, J. Ciccolini
2020Clinical pharmacology and therapy31 citations
Semantic Scholar
Cross-Validation of a Multiplex LC-MS/MS Method for Assaying mAbs Plasma Levels in Patients with Cancer: A GPCO-UNICANCER Study
Clémence Marin, N. Khoudour, Aurélien Millet, Dorothée Lebert +7 more
2021Pharmaceuticals26 citations Open access
Semantic Scholar
Quantitative impact of pre‐analytical process on plasma uracil when testing for dihydropyrimidine dehydrogenase deficiency
Maud Maillard, M. Launay, B. Royer, J. Guitton +13 more
2022British Journal of Clinical Pharmacology25 citations Open access
Semantic Scholar
Pharmacology and pharmacokinetics of antibody-drug conjugates, where do we stand?
Arthur Géraud, Paul Gougis, A. de Nonneville, Mathilde Beaufils +17 more
2025Cancer Treatment Reviews24 citations
Semantic Scholar
Tumor growth monitoring in breast cancer xenografts: A good technique for a strong ethic
A. Rodallec, C. Vaghi, J. Ciccolini, R. Fanciullino +1 more
2022PLoS ONE21 citations Open access
Semantic Scholar
Enhanced Antisense Oligonucleotide Delivery Using Cationic Liposomes Grafted with Trastuzumab: A Proof-of-Concept Study in Prostate Cancer
G. Sicard, Clément Paris, S. Giacometti, A. Rodallec +3 more
2020Pharmaceutics21 citations Open access
Semantic Scholar
Prototyping Trastuzumab Docetaxel Immunoliposomes with a New FCM-Based Method to Quantify Optimal Antibody Density on Nanoparticles
A. Rodallec, Corentin Franco, S. Robert, G. Sicard +9 more
2020Scientific Reports18 citations Open access
Semantic Scholar
A non-inferiority randomized phase III trial of standard immunotherapy by checkpoint inhibitors vs. reduced dose intensity in responding patients with metastatic cancer: the MOIO protocol study
G. Gravis, P. Marino, Daniel Olive, F. Penault-Llorca +6 more
2023BMC Cancer17 citations Open access
Semantic Scholar
Deciphering the response and resistance to immune-checkpoint inhibitors in lung cancer with artificial intelligence-based analysis: when PIONeeR meets QUANTIC
J. Ciccolini, S. Benzekry, F. Barlesi
2020British Journal of Cancer17 citations Open access
Semantic Scholar
Combinatorial Immunotherapy Strategies: most Gods throw Dice, but fate plays Chess.
J. Ciccolini, D. Barbolosi, Nicolas André, S. Benzekry +1 more
2019Annals of Oncology17 citations Open access
Semantic Scholar
Tumor uptake and associated greater efficacy of anti-Her2 immunoliposome does not rely on Her2 expression status: study of a docetaxel-trastuzumab immunoliposome on Her2+ breast cancer model (SKBR3)
A. Rodallec, G. Sicard, S. Giacometti, M. Carré +7 more
2019Anti-Cancer Drugs16 citations
Semantic Scholar
MOVIE: a phase I, open-label, multicenter study to evaluate the safety and tolerability of metronomic vinorelbine combined with durvalumab plus tremelimumab in patients with advanced solid tumors
C. Vicier, N. Isambert, C. Cropet, M. Hamimed +5 more
2022ESMO Open15 citations Open access
Semantic Scholar
Mechanistic Learning for Combinatorial Strategies With Immuno-oncology Drugs: Can Model-Informed Designs Help Investigators?
J. Ciccolini, D. Barbolosi, N. André, F. Barlesi +1 more
2020JCO Precision Oncology15 citations Open access
Semantic Scholar
A Simple and Rapid UPLC‐UV Method for Detecting DPD Deficiency in Patients With Cancer
Clémence Marin, A. Krache, Chloé Palmaro, M. Lucas +7 more
2020Clinical and Translational Science14 citations Open access
Semantic Scholar
Pharmacodynamic Therapeutic Drug Monitoring for Cancer: Challenges, Advances, and Future Opportunities.
G. Veal, E. Amankwatia, Marie-Noëlle Paludetto, Till Möcklinghoff +4 more
2019Therapeutic Drug Monitoring12 citations Open access
Semantic Scholar
Pegylated liposome encapsulating docetaxel using microfluidic mixing technique: process optimization and results in breast cancer models.
M. Dacos, B. Immordino, E. Diroff, G. Sicard +5 more
2024International journal of pharmaceutics11 citations Open access
Semantic Scholar
Clinical-Based vs. Model-Based Adaptive Dosing Strategy: Retrospective Comparison in Real-World mRCC Patients Treated with Sunitinib
Florent Ferrer, Jonathan Chauvin, B. Devictor, B. Lacarelle +2 more
2021Pharmaceuticals11 citations Open access
Semantic Scholar
LBA53 Precision immuno-oncology for advanced non-small cell lung cancer (NSCLC) patients (pts) treated with PD1/L1 immune checkpoint inhibitors (ICIs): A first analysis of the PIONeeR study
F. Barlesi, L. Greillier, F. Monville, C. Foa +16 more
202011 citations
Semantic Scholar
Simultaneous determination of cytosine arabinoside and its metabolite uracil arabinoside in human plasma by LC-MS/MS: Application to pharmacokinetics-pharmacogenetics pilot study in LAM patients.
M. Donnette, C. Solas, M. Giocanti, G. Venton +8 more
2019Journal of chromatography. B, Analytical technologies in the biomedical and life sciences11 citations Open access
Semantic Scholar
Can cytidine deaminase be used as predictive biomarker for gemcitabine toxicity and response?
G. Peters, E. Giovannetti, R. Honeywell, J. Ciccolini
2019British Journal of Clinical Pharmacology11 citations Open access
Semantic Scholar
Killing a fly with a sledgehammer: Atezolizumab exposure in real‐world lung cancer patients
S. Marolleau, A. Mogenet, Clara Boéri, Mourad Hamimed +2 more
2023CPT: Pharmacometrics & Systems Pharmacology10 citations Open access
Semantic Scholar
Optimal Scheduling of Bevacizumab and Pemetrexed/Cisplatin Dosing in Non‐Small Cell Lung Cancer
Benjamin K. Schneider, Arnaud Boyer, J. Ciccolini, F. Barlesi +3 more
2019bioRxiv10 citations Open access
Semantic Scholar
Pharmacokinetics and pharmacogenetics of liposomal cytarabine in AML patients treated with CPX-351.
M. Donnette, Mourad Hamimed, J. Ciccolini, Y. Berda-Haddad +7 more
2021Journal of Controlled Release9 citations Open access
Semantic Scholar
A simple and rapid liquid chromatography-mass spectrometry method to assay cabozantinib in plasma: Application to therapeutic drug monitoring in patients with renal cell carcinoma.
Florent Ferrer, C. Solas, M. Giocanti, B. Lacarelle +3 more
2020Journal of chromatography. B, Analytical technologies in the biomedical and life sciences9 citations Open access
Semantic Scholar
Lethal toxicities after capecitabine intake in a previously 5-FU-treated patient: why dose matters with dihydropryimidine dehydrogenase deficiency.
Crescent C Gbeto, Sylvie Quaranta, Roxane Mari, R. Fanciullino +7 more
2019Pharmacogenomics (London)9 citations
Semantic Scholar
Impact of renal impairment on dihydropyrimidine dehydrogenase (DPD) phenotyping
B. Royer, M. Launay, J. Ciccolini, L. Derain +3 more
2023ESMO Open8 citations Open access
Semantic Scholar
Pancreatic ductal adenocarcinoma ubiquitination profiling reveals specific prognostic and theranostic markers
A. Elkaoutari, N. Fraunhoffer, S. Audebert, L. Camoin +9 more
2023EBioMedicine8 citations Open access
Semantic Scholar
Machine-Learning Exploration of Exposure-Effect Relationships of Cisplatin in Head and Neck Cancer Patients
Céleste Cauvin, L. Bourguignon, Laure Carriat, Abel Mence +3 more
2022Pharmaceutics8 citations Open access
Semantic Scholar
Like a Rolling Stone: Sting-Cgas Pathway and Cell-Free DNA as Biomarkers for Combinatorial Immunotherapy
G. Sicard, F. Fina, R. Fanciullino, F. Barlesi +1 more
2020Pharmaceutics8 citations Open access
Semantic Scholar
HIGH INCIDENCE OF CDA DEFICIENCY IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES: PERSPECTIVES AND THERAPEUTIC IMPLICATIONS.
M. Donnette, J. Ciccolini, C. Pissier, R. Costello +9 more
2021Annals of Oncology7 citations Open access
Semantic Scholar
Pharmacogenetics and pharmacokinetics modeling of unexpected and extremely severe toxicities after sorafenib intake.
Hai-Le Ba, L. Mbatchi, Florence Gattacceca, A. Evrard +4 more
2020Pharmacogenomics (London)7 citations
Semantic Scholar
Cytidine deaminase status as a marker of response to azacytidine treatment in MDS and AML patients
M. Donnette, Mourad Hamimed, J. Ciccolini, G. Sicard +5 more
2023British Journal of Haematology6 citations Open access
Semantic Scholar
Revisiting metronomic vinorelbine with mathematical modelling: a Phase I trial in lung cancer
F. Barlesi, Laure Deyme, D. Imbs, Elissa Cousin +10 more
2022Cancer Chemotherapy and Pharmacology6 citations
Semantic Scholar
Fewer cetuximab-related skin-toxicities in colorectal cancer patients treated with encorafenib: a Yin and Yang effect of ERK paradoxical activation.
J. Ciccolini, G. Milano
2022Annals of Oncology6 citations Open access
Semantic Scholar
Multicentric phase II trial of TI‐CE high‐dose chemotherapy with therapeutic drug monitoring of carboplatin in patients with relapsed advanced germ cell tumors
C. Chevreau, C. Massard, A. Flechon, R. Delva +17 more
2021Cancer Medicine6 citations Open access
Semantic Scholar
Is There Any Room for Pharmacometrics With Immuno-Oncology Drugs? Input from the EORTC-PAMM Course on Preclinical and Early-phase Clinical Pharmacology
A. Rodallec, R. Fanciullino, S. Benzekry, J. Ciccolini
2019Anticancer Research6 citations Open access
Semantic Scholar
Overcoming immuno-resistance by rescheduling anti-VEGF/cytotoxics/anti-PD-1 combination in lung cancer model
G. Sicard, D. Protzenko, S. Giacometti, Fabrice Barlési +2 more
2024Cancer Drug Resistance5 citations Open access
Semantic Scholar
Immune check points in cancer treatment: current challenges and perspectives
J. Ciccolini, G. Milano
2023British Journal of Cancer5 citations Open access
Semantic Scholar
Renal impairment and DPD testing: Watch out for false‐positive results!
Laure Carriat, Sylvie Quaranta, C. Solas, M. Rony +1 more
2022British Journal of Clinical Pharmacology5 citations Open access
Semantic Scholar
Estimation of Unbound Carboplatin Clearance From Total Plasma Concentrations as a Means of Facilitating Therapeutic Drug Monitoring
Sotheara Moeung, C. Chevreau, V. Poinsignon, J. Guitton +15 more
2019Therapeutic Drug Monitoring5 citations
Semantic Scholar
[Dihydropyrimidine dehydrogenase deficiency screening for management of patients receiving a fluoropyrimidine: Results of two national practice surveys addressed to clinicians and biologists].
M. Loriot, F. Masskouri, P. Carni, K. Le Malicot +15 more
2019Bulletin du Cancer5 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

R. Fanciullino×17
Invite
R. Fanciullino — researcher profile on SciRah
B. Lacarelle×11
Invite
B. Lacarelle — researcher profile on SciRah
A. Rodallec×8
Invite
A. Rodallec — researcher profile on SciRah
S. Benzekry×8
Invite
S. Benzekry — researcher profile on SciRah

×7

Invite

F. Thomas — researcher profile on SciRah

Invite

G. Sicard — researcher profile on SciRah

Invite

F. Barlesi — researcher profile on SciRah

Invite

E. Chatelut — researcher profile on SciRah

S. Giacometti×5

Invite

S. Giacometti — researcher profile on SciRah

Invite

C. Solas — researcher profile on SciRah

Invite

G. Milano — researcher profile on SciRah

Invite

J. Guitton — researcher profile on SciRah